Search results for " colore."

showing 10 items of 234 documents

Tumor budding as a risk factor for nodal metastasis in pT1 colorectal cancers: a meta-analysis

2017

Worldwide, colorectal cancer (CRC) screening programs have significantly increased the detection of submucosal (pT1) adenocarcinoma. Completion surgery may be indicated after endoscopic excision of these potentially metastasizing early cancers. However, the postsurgical prevalence of nodal implants does not exceed 15%, leading to questions concerning the clinical appropriateness of any post–endoscopy surgery. Eastern scientific societies (Japanese Society for Cancer of the Colon-Rectum, in particular) include tumor budding (TB), defined as the presence of isolated single cancer cells or clusters of fewer than 5 cancer cells at the tumor invasive front, among the variables that must be inclu…

Oncologymedicine.medical_specialtyColorectal cancerBiopsyTumor buddingAdenocarcinomaRisk AssessmentPathology and Forensic MedicineColorectal cancer; Lymph node metastasis; Meta-analysis; Sprouting; Tumor buddingColorectal cancer; Lymph node metastasis; Meta-analysis; Sprouting; Tumor budding; Adenocarcinoma; Biopsy; Colorectal Neoplasms; Humans; Lymph Nodes; Lymphatic Metastasis; Neoplasm Invasiveness; Neoplasm Staging; Odds Ratio; Predictive Value of Tests; Risk Assessment; Risk Factors; Cell MovementLymph node metastasi03 medical and health sciences0302 clinical medicineTumor buddingPredictive Value of TestsRisk FactorsCell MovementTumor budding.Internal medicineBiopsymedicineOdds RatioHumansMeta-analysiNeoplasm InvasivenessRisk factorNeoplasm StagingLymph node metastasismedicine.diagnostic_testbusiness.industryCancerOdds ratiomedicine.diseaseColorectal cancerSurgeryMeta-analysis030220 oncology & carcinogenesisPredictive value of testsLymphatic MetastasisAdenocarcinoma030211 gastroenterology & hepatologyLymph NodesbusinessColorectal NeoplasmsSprouting
researchProduct

CD133 as a target for colon cancer.

2012

INTRODUCTION: Recent evidence based on cancer stem cell (CSC) models, is boosting the progress of translational research and providing relevant clinical implications in many tumour types, including colorectal cancer. The current failure of standard therapies is attributed to a small fraction of the primary cell population with stem-like characteristics, such as self-renewal and differentiation. Identification of CSCs is based on two different criteria of selection: stemness-selective conditions and direct isolation based on putative stem cell markers expression. CD133, a transmembrane glycoprotein, was associated with tumor-initiating cells derived from several histological variants of tumo…

Oncologymedicine.medical_specialtyColorectal cancerClinical BiochemistryCellPopulationTranslational researchBiologyStem cell markerAntigenCancer stem cellAntigens CDInternal medicineDrug DiscoverymedicineTransmembrane glycoproteinAnimalsHumansAC133 AntigeneducationGlycoproteinsPharmacologyeducation.field_of_studymedicine.diseasemedicine.anatomical_structureCD133 colon carcinogenesis colorectal CSCs stemness markers.Neoplastic Stem CellsMolecular MedicineColorectal NeoplasmsPeptides
researchProduct

Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment.

2010

Oncologymedicine.medical_specialtyColorectal cancerDisease-Free SurvivalAdvanced colorectal cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasm MetastasisNeoplasm StagingRandomized Controlled Trials as TopicCetuximabbusiness.industryIncidenceCancerAntibodies MonoclonalHematologymedicine.diseaseChemotherapy regimenOxaliplatinCarcinoembryonic AntigenIrinotecanClinical PracticeEuropeTreatment OutcomeOncologybusinessColorectal Neoplasmsmedicine.drugFollow-Up StudiesAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Prognostic Value of Sarcopenia in Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil

2021

Sarcopenia is common in metastatic colorectal cancer (mCRC), increases the risk of treatment-related toxicity and reduces survival. Trifluridine/tipiracil (TT) chemotherapy significantly improved survival in refractory mCRC patients, but the prognostic and predictive role of pretherapeutic sarcopenia and variation in the skeletal muscle index (SMI) during this treatment has not been investigated so far. In this retrospective, observational study, clinical data on mCRC patients treated with TT at six cancer centres in Poland were collected. Computed tomography (CT) scans acquired at the time of initiation of TT (CT1) and on the first restaging (CT2), were evaluated. SMI was assessed based on…

Oncologymedicine.medical_specialtyColorectal cancermedicine.medical_treatmentTrifluridineArticletrifluridine/tipiracilsarcopeniachemistry.chemical_compoundCarcinoembryonic antigenInternal medicineMedicineTipiracilChemotherapyPerformance statusbiologybusiness.industrymetastatic colorectal cancerRCancerGeneral Medicinemedicine.diseasechemistrySarcopeniabiology.proteinMedicinebusinessmedicine.drugcancer cachexiaJournal of Clinical Medicine
researchProduct

TAS-102 in metastatic colorectal cancer (mCRC): efficacy, tolerability, and quality of life in heavily pretreated elderly patients: a real-life study

2020

Background: TAS-102 is an oral monotherapy, combining trifluridine and tipiracil hydrochloride, indicated for the treatment of pretreated metastatic colorectal cancer (mCRC). The aim of this real-life study is to evaluate the efficacy and safety of TAS-102 in heavily pretreated elderly patients with mCRC whose disease has progressed with standard therapies. Methods: In this retrospective observational study, we enrolled 50 elderly patients >70 years of age (median age 78 years) with a diagnosis of mCRC who were previously treated or were not considered candidates for treatment with other available therapies. Patients aged >70 years with advanced colorectal cancer and with an ECOG perf…

Oncologymedicine.medical_specialtyColorectal cancermedicine.medical_treatmentTrifluridineECOG Performance StatusDiseasechemotherapyelderly patientstrifluridine/tipiracilQuality of lifeInternal medicinemedicinelonsurfOriginal ResearchPharmacologyChemotherapybusiness.industrymetastatic colorectal cancertrifluridine/ tipiracillcsh:RM1-950Retrospective cohort studyGeneral Medicinemedicine.diseaselcsh:Therapeutics. PharmacologyTolerabilityquality of lifetas-102Molecular Medicinebusinessmedicine.drugDrugs in Context
researchProduct

Definition and management of colorectal polyposis not associated with APC/MUTYH germline pathogenic variants: AIFEG consensus statement

2021

An expert consensus panel convened by the Italian Association for Inherited and Familial Gastrointestinal Tumors (Associazione Italiana per lo Studio della Familiarita ed Ereditarieta dei Tumori Gastrointestinali, AIFEG) reviewed the literature and agreed on a number of position statements regarding the definition and management of polyposis coli without an identified pathogenic mutation on the APC or MUTYH genes, defined in the document as NAMP (non-APC/MUTYH polyposis).

Oncologymedicine.medical_specialtyGastrointestinal tumorsColorectal cancerSurgical ManagementColorectal polyposisGermline03 medical and health sciencesCancer Genetic0302 clinical medicineMUTYHInternal medicinemedicineCancer GeneticsPolyposis coliHepatologyPathogenic mutationbusiness.industryColorectal polyposis not associated with APC/MUTYH mutationPolyposis management guidelineGastroenterologyExpert consensusEndoscopic surveillancemedicine.diseaseColorectal cancerConsensus development conference030220 oncology & carcinogenesisCancer Genetics; Colorectal cancer; Colorectal polyposis not associated with APC/MUTYH mutation; Consensus development conference; Endoscopic surveillance; Polyposis management guideline; Surgical Management030211 gastroenterology & hepatologybusiness
researchProduct

How to find the Ariadne's thread in the labyrinth of salvage treatment options for metastatic colorectal cancer?

2014

Abstract: Since a chance for cure was found out in metastatic colorectal cancer (mCRC) patients undergoing a resection of liver and lung metastases, high tumor shrinkage by chemotherapy regimens and their combination with targeted agents have been addressed in potentially resectable mCRC. However, most mCRC patients cannot reach this opportunity because of tumor burden or metastatic sites. For these patients a salvage systemic therapy could be offered to prolong survival. To date, a huge number of clinical trials provided some evidences for the achievement of this goal. A lot of chemotherapeutic regimens in combination with biological therapies are now available. We tried to propose a simpl…

Oncologymedicine.medical_specialtyLung NeoplasmsColorectal cancerSettore MED/06 - Oncologia Medicamedicine.medical_treatmentClinical BiochemistrySalvage treatmentTumor burdenalgorithm chemotherapy metastatic colorectal cancer salvage treatment target therapySystemic therapyResectionInternal medicineDrug DiscoveryAntineoplastic Combined Chemotherapy ProtocolsmedicineHepatectomyHumansMolecular Targeted TherapyPneumonectomyBiologyPharmacologySalvage TherapyChemotherapybusiness.industryPatient SelectionTumor shrinkageLiver NeoplasmsMetastasectomymedicine.diseasedigestive system diseasesNeoadjuvant TherapyClinical trialTreatment OutcomeChemotherapy AdjuvantCritical PathwaysHuman medicinebusinessColorectal NeoplasmsEngineering sciences. TechnologyAlgorithms
researchProduct

Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study.

2006

Item does not contain fulltext BACKGROUND: Loss of TP53 function through gene mutation is a critical event in the development and progression of many tumour types including colorectal cancer (CRC). In vitro studies have found considerable heterogeneity amongst different TP53 mutants in terms of their transactivating abilities. The aim of this work was to evaluate whether TP53 mutations classified as functionally inactive (< or=20% of wildtype transactivation ability) had different prognostic and predictive values in CRC compared with mutations that retained significant activity. MATERIALS AND METHODS: TP53 mutations within a large, international database of CRC (n = 3583) were classified ac…

Oncologyp53MaleNutrition and Diseasebinding domainsLymphovascular invasionColorectal cancerDNA Mutational AnalysisAetiology screening and detection [ONCOL 5]Gene mutationmedicine.disease_causeTransactivationVoeding en ZiekteAntineoplastic Combined Chemotherapy ProtocolsDeterminants in Health and Disease [EBP 1]transcriptional activityMutationHematologyExonsMiddle AgedSurvival RateOncologyAdenocarcinomaFemaleColorectal Neoplasmsmedicine.medical_specialtyAdenocarcinomachemotherapy colorectal cancer mutation prognosis TP53 transactivational abilityMolecular epidemiology [NCEBP 1]Breast cancerTranslational research [ONCOL 3]Interventional oncology [UMCN 1.5]Internal medicinemedicineHumansNeoplasm InvasivenessSurvival rateneoplasmsbreast-cancerVLAGAgedNeoplasm StagingHereditary cancer and cancer-related syndromes [ONCOL 1]business.industryInternational Agenciesmedicine.diseaseImmunologyMutationTumor Suppressor Protein p53businessFollow-Up Studies
researchProduct

Copper(I) Bromide: An Alternative Emitter for Blue-Colored Flame Pyrotechnics.

2015

Copper(I) bromide was evaluated as an alternative emitter for blue flame pyrotechnic compositions. CuBr and CuCl emission spectra were recorded from a butane torch flame and compared. Cu(BrO3 )2 was synthesized and used in pyrotechnic compositions as an oxidizer and the source for the generation of CuBr species. Pyrotechnic compositions, which contained copper and potassium bromates as oxidizers, were optimized for the generation of blue flames. The experimental data, including emission spectra of the flames, chromaticity coordinates, burning rates, luminous intensities, and sensitivity tests, were analyzed and compared.

Organic ChemistryAnalytical chemistryPyrotechnicschemistry.chemical_elementCopper(I) bromideNanotechnologyButaneGeneral ChemistryCopperCatalysischemistry.chemical_compoundBlue coloredchemistryBromideEmission spectrumChromaticityChemistry (Weinheim an der Bergstrasse, Germany)
researchProduct

Rôle de l’hypotonie dans la réponse à la chimiothérapie intra-péritonéale : étude des effets sur les cellules cancéreuses et la mort immunogène indui…

2018

IntraPeritoneal Chemotherapy (IPEC) is commonly used to treat colorectal cancer metastases. However there is no standardized protocol.The aim of this work was to model this chemotherapy in vitro and to understand the role of hypotonic conditions in this model and its impact on cell death.We determined that the optimal treatment parameters on HCT116 human colon cancer cells, were an exposure of the cells for 30 minutes to 400μM of oxaliplatin under hypotonic conditions (G2.5%) at 37 °C. These results have been validated on various human and murine colic cancer cell lines. We have also shown that these treatment conditions are also able to increase the cytotoxicity of other platinum derivativ…

OxaliplatinCancer colorectal[SDV.BBM] Life Sciences [q-bio]/Biochemistry Molecular BiologyHypotonia[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyChimiothérapie intrapéritonéaleIntraperitoneal chemotherapyColorectal cancerOxaliplatineHypotonie
researchProduct